Paper32676151
2-Aminooxazole as a Novel Privileged Scaffold in Antitubercular Medicinal Chemistry.
Azzali E and 8 others. ACS Med Chem Lett, 2020. Cited by 16 papers, by iCite.
Cite this record
ConductScience Library. 2-Aminooxazole as a Novel Privileged Scaffold in Antitubercular Medicinal Chemistry. Papers, record 32676151. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32676151
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References20
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28749666 | Substituted N-Phenyl-5-(2-(phenylamino)thiazol-4-yl)isoxazole-3-carboxamides Are Valuable Antitubercular Candidates that Evade Innate Efflux Machinery. | J Med Chem | 2017 | https://conductscience.org/library/papers/28749666 | PubMed |
| 2 | 11848856 | Bioisosterism: A Rational Approach in Drug Design. | Chem Rev | 1996 | https://conductscience.org/library/papers/11848856 | PubMed |
| 3 | 11745742 | High throughput physicochemical profiling for drug discovery. | J Pharm Sci | 2001 | https://conductscience.org/library/papers/11745742 | PubMed |
| 4 | 22394197 | Palladium-catalyzed N-arylation of 2-aminothiazoles. | Org Lett | 2012 | https://conductscience.org/library/papers/22394197 | PubMed |
| 5 | 28605135 | Mechanistic Insight Leads to a Ligand Which Facilitates the Palladium-Catalyzed Formation of 2-(Hetero)Arylaminooxazoles and 4-(Hetero)Arylaminothiazoles. | Angew Chem Int Ed Engl | 2017 | https://conductscience.org/library/papers/28605135 | PubMed |
| 6 | 28344011 | The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. | Lancet Respir Med | 2017 | https://conductscience.org/library/papers/28344011 | PubMed |
| 7 | 31766441 | Strategies to Overcome Antimicrobial Resistance (AMR) Making Use of Non-Essential Target Inhibitors: A Review. | Int J Mol Sci | 2019 | https://conductscience.org/library/papers/31766441 | PubMed |
| 8 | 20131845 | New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. | J Med Chem | 2010 | https://conductscience.org/library/papers/20131845 | PubMed |
| 9 | 30259757 | Adjuvant therapies against tuberculosis: discovery of a 2-aminothiazole targeting Mycobacterium tuberculosis energetics. | Future Microbiol | 2018 | https://conductscience.org/library/papers/30259757 | PubMed |
| 10 | 25559643 | Promiscuous 2-aminothiazoles (PrATs): a frequent hitting scaffold. | J Med Chem | 2015 | https://conductscience.org/library/papers/25559643 | PubMed |
| 11 | 24333612 | Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents. | Eur J Med Chem | 2014 | https://conductscience.org/library/papers/24333612 | PubMed |
| 12 | 22784641 | Ultrasound and deep eutectic solvent (DES): a novel blend of techniques for rapid and energy efficient synthesis of oxazoles. | Ultrason Sonochem | 2013 | https://conductscience.org/library/papers/22784641 | PubMed |
| 13 | 29202222 | Seven Year Itch: Pan-Assay Interference Compounds (PAINS) in 2017-Utility and Limitations. | ACS Chem Biol | 2018 | https://conductscience.org/library/papers/29202222 | PubMed |
| 14 | 10534321 | Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. | Drug Metab Dispos | 1999 | https://conductscience.org/library/papers/10534321 | PubMed |
| 15 | 17868596 | First tuberculosis cases in Italy resistant to all tested drugs. | Euro Surveill | 2007 | https://conductscience.org/library/papers/17868596 | PubMed |
| 16 | 26071857 | Discovery of antitubercular 2,4-diphenyl-1H-imidazoles from chemical library repositioning and rational design. | Eur J Med Chem | 2015 | https://conductscience.org/library/papers/26071857 | PubMed |
| 17 | 30144650 | The present state of the tuberculosis drug development pipeline. | Curr Opin Pharmacol | 2018 | https://conductscience.org/library/papers/30144650 | PubMed |
| 18 | 26197353 | Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy. | J Med Chem | 2015 | https://conductscience.org/library/papers/26197353 | PubMed |
| 19 | 32353943 | Antibacterial Discovery: 21st Century Challenges. | Antibiotics (Basel) | 2020 | https://conductscience.org/library/papers/32353943 | PubMed |
| 20 | 29529363 | Breaking the Base Barrier: An Electron-Deficient Palladium Catalyst Enables the Use of a Common Soluble Base in C-N Coupling. | J Am Chem Soc | 2018 | https://conductscience.org/library/papers/29529363 | PubMed |
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 16 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42899217 | 2-Aminooxazoles and 2-aminothiazoles: green regioselective synthesis and bioactivity. | RSC Adv | 2026 | https://conductscience.org/library/papers/42899217 | PubMed |
| 40971029 | A new bactericidal chlorinated derivative containing 2-aminooxazole potentiates antibacterial action of colistin against multidrug-resistant acinetobacter baumannii. | Med Microbiol Immunol | 2025 | https://conductscience.org/library/papers/40971029 | PubMed |
| 40806215 | Therapeutic Potential of Isoxazole-(Iso)oxazole Hybrids: Three Decades of Research. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40806215 | PubMed |
| 40649348 | Azirinyl-Substituted Nitrile Oxides: Generation and Use in the Synthesis of Isoxazole Containing Heterocyclic Hybrids. | Molecules | 2025 | https://conductscience.org/library/papers/40649348 | PubMed |
| 38415251 | Complementary supramolecular drug associates in perfecting the multidrug therapy against multidrug resistant bacteria. | Front Immunol | 2024 | https://conductscience.org/library/papers/38415251 | PubMed |
| 36399878 | Expanding the knowledge around antitubercular 5-(2-aminothiazol-4-yl)isoxazole-3-carboxamides: Hit-to-lead optimization and release of a novel antitubercular chemotype via scaffold derivatization. | Eur J Med Chem | 2023 | https://conductscience.org/library/papers/36399878 | PubMed |
| 35631406 | Improving Antimicrobial Activity and Physico-Chemical Properties by Isosteric Replacement of 2-Aminothiazole with 2-Aminooxazole. | Pharmaceuticals (Basel) | 2022 | https://conductscience.org/library/papers/35631406 | PubMed |
| 33672408 | Discovery of Substituted (2-Aminooxazol-4-yl)Isoxazole-3-carboxylic Acids as Inhibitors of Bacterial Serine Acetyltransferase in the Quest for Novel Potential Antibacterial Adjuvants. | Pharmaceuticals (Basel) | 2021 | https://conductscience.org/library/papers/33672408 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32676151
GET https://conductscience.org/api/papers/v1/32676151/authors